LAX.SH
MONO PHARMACARE LIMITED·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
11
+0%O:11
H:11
L:11
C:11
52W Range
9.4527.5
+16%/-60%
Market Cap
₹19.44 Cr
Traded: ₹0.00 Cr (0.01%) 0.0x
Free Float: ₹5.42 Cr (0.04% of FF traded)
Volume · 60D trend
2 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
1W:+0% 1M:+0% 3M:-16% 6M:-6% 12M:-45%
Valuation
P/E23.4
P/B0.6
P/S0.1
EV/EBIT12.6
Business Strength
ROE10.4%
ROCE11.0%
OPM4.8%
NPM1.8%
Growth (3Y CAGR)
EPS+26.8%
Sales--
Profit--
3Y Return--
Balance Sheet
Debt/Equity1.7
Debt55 Cr
Pledge0.0%
CWIP/Fixed Asset0.0%
Cash Position
CFO/NP-133.3%
FCF-4.53 Cr
FCF 3Y Avg-42.1 Cr
Cash/MCap3.0%
Others
Div Yield0.0%
Div Payout0.0%
Cash Conv. Cycle179 days
Tradeable Free Float27.9%
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | +10.0% | -- | -- | -- |
| Sales | -- | -- | -- | -- | +3.0% | -- |
| Profit | -- | -- | -- | -- | -71.0% | -- |
| Return | -- | -- | -- | -57.0% | -- | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Debt / Equity1.72
Interest Coverage-2.4x
Promoter Pledge0.0%
Borrowings55 Cr
Efficiency
Receivable Days91 days
Inventory Days133 days
Payable Days45 days
Cash Conversion cycle179 days
Cash Position
Operating Cash Flow-4 Cr
Investing Cash Flow0 Cr
Financing Cash Flow5 Cr
Free Cash Flow-5 Cr
Detailed Financials
Sep 2025PDF ↗ | Mar 2025PDF ↗ | Sep 2024PDF ↗ | Mar 2024PDF ↗ | Sep 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|
| Sales | 66 | 81 | 87 | 56 | 67 | 35 |
| Expenses | 65 | 78 | 82 | 53 | 63 | 33 |
| Operating Profit | 2 | 3 | 5 | 2 | 4 | 2 |
| OPM % | 3.0% | 4.0% | 5.0% | 4.0% | 6.0% | 6.0% |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 3 | 1 | 2 | 1 |
| Tax % | 83.0% | 37.0% | 27.0% | 33.0% | 20.0% | 39.0% |
| Net Profit | 0 | 1 | 2 | 1 | 2 | 1 |
| Exceptional Items | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.0 | 0.5 | 1.3 | 0.3 | 1.1 | 0.5 |
| Sales Growth (YoY) | -24.1% | 44.6% | 29.9% | 60.0% | -- | -- |
| Sales Growth (QoQ) | -18.5% | -6.9% | 55.4% | -16.4% | 91.4% | -- |
| OP Growth (YoY) | -60.0% | 50.0% | 25.0% | 0.0% | -- | -- |
| OP Growth (QoQ) | -- | -- | -- | -- | -- | -- |
| Profit Growth (YoY) | -- | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | -99.2% | 39.4% | 22.6% | -36.5% | -- | -- |
| EPS Growth (QoQ) | -97.8% | -64.6% | 293.9% | -68.9% | 103.8% | -- |
| OP Margin | 3.0% | 3.7% | 5.8% | 3.6% | 6.0% | 5.7% |
| Net Margin | 0.0% | 1.2% | 2.3% | 1.8% | 3.0% | 2.9% |
| Material Cost % | 93.0% | 90.0% | 91.0% | 90.0% | 91.0% | 90.0% |
| Employee Cost % | 3.0% | 3.0% | 2.0% | 3.0% | 3.0% | 3.0% |
| P/S | 0.13 | -- | -- | -- | -- | -- |
| P/E | 23.40 | -- | -- | -- | -- | -- |
| P/B | 0.61 | -- | -- | -- | -- | -- |